company background image
BDRX logo

Biodexa Pharmaceuticals NasdaqCM:BDRX Stock Report

Last Price

US$1.62

Market Cap

US$2.3m

7D

52.9%

1Y

-95.2%

Updated

28 Mar, 2024

Data

Company Financials +

Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stock Report

Market Cap: US$2.3m

BDRX Stock Overview

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.

BDRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Biodexa Pharmaceuticals Plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biodexa Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.62
52 Week HighUS$36.80
52 Week LowUS$0.72
Beta1.44
1 Month Change17.39%
3 Month Change-39.55%
1 Year Change-95.20%
3 Year Change-99.96%
5 Year Change-99.99%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Shareholder Returns

BDRXUS BiotechsUS Market
7D52.9%0.9%0.2%
1Y-95.2%11.0%28.1%

Return vs Industry: BDRX underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BDRX underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is BDRX's price volatile compared to industry and market?
BDRX volatility
BDRX Average Weekly Movement29.6%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BDRX's share price has been volatile over the past 3 months.

Volatility Over Time: BDRX's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200027Stephen Stamphttps://www.biodexapharma.com

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.

Biodexa Pharmaceuticals Plc Fundamentals Summary

How do Biodexa Pharmaceuticals's earnings and revenue compare to its market cap?
BDRX fundamental statistics
Market capUS$2.25m
Earnings (TTM)-US$10.30m
Revenue (TTM)US$667.65k

6.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDRX income statement (TTM)
RevenueUK£529.00k
Cost of RevenueUK£4.95m
Gross Profit-UK£4.42m
Other ExpensesUK£3.74m
Earnings-UK£8.16m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.12
Gross Margin-835.54%
Net Profit Margin-1,543.10%
Debt/Equity Ratio0%

How did BDRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.